FDA’s Off-Label Dissemination Guidance Opens “Loophole” – Rep. Waxman

Rep. Henry Waxman, D-Calif., made another move in his fight against off-label drug promotion Nov. 30, releasing an internal FDA 1draft guidance on "good reprint practices" and sending a strongly worded 2letter to Commissioner Andrew von Eschenbach